title: Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
abstract: Raltegravir and lamivudine have been part of highly active therapy regimens throughout the past years of antiretroviral therapy. A fixed-dose, single-tablet regimen comprising a non-poloxamer formulation of the integrase inhibitor raltegravir and the transcriptase inhibitor lamivudine (raltegravir/lamivudine; Dutrebis(®)) has been recently licensed for the treatment of HIV-1 infection. In several Phase I pharmacokinetic studies, one Dutrebis (150 mg lamivudine/300 mg raltegravir) fixed-dose combination tablet showed a higher bioavailability but comparable lamivudine and 400 mg raltegravir poloxamer exposures. Thus, the co-administration of raltegravir together with lamivudine created a potent, effective, well-tolerated antiretroviral combination, which could be more convenient for the patient. However, the disadvantage of twice a day administration, and the existence of other fixed-dose combinations limit its widespread clinical use. This article reviews pharmacokinetics data and appraises their potential use in current and future HIV therapy.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Casado
authors.affiliation: a Department of Infectious Diseases, HIV Unit, Ramón y Cajal Hospital , Madrid, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Bañón
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001682:Biological Availability; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068898:Raltegravir Potassium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013607:Tablets
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D013607:Tablets; D019259:Lamivudine; D000068898:Raltegravir Potassium
keywords: Dutrebis; bioavailability; fixed-dose combination; formulation; integrase inhibitors; lamivudine; pharmacokinetics; raltegravir